Vertigo Clinical Trial - Evaluation of Aminobutyric Acid, Glutamic Acid,

Status Completed

Clinical Trial Summary

The goal of this clinical trial is to assess the efficacy and safety of a combination of aminobutyric acid, glutamic acid, calcium, thiamine, pyridoxine and cyanocobalamin as adjuvant therapy for vertigo comparatively to ginger under a double-blind randomized study design.

Clinical Trial Description

Motion sickness is a chronic condition characterized by vestibular changes in response to stimuli caused either by movement or movement perception triggered by car, train, ship or aircraft transportation, amusement park rides, virtual reality and simulators, walking, exercising, as well as under the absence of gravity in space.The studied combination drug is composed by GABA (gamma-aminobutyric acid), the main inhibitory neurotransmitter of the central nervous system. The former lowers anxiety symptoms. Its precursor, glutamic acid, is the amino acid found in greater concentration under free form in the CNS; it is closely related to brain metabolism and, in contrast to GABA, it is the main excitatory neurotransmitter; glutamic acid also has anxyolytic therapeutic properties. Thiamine or vitamin B1 is a cofactor in the synthesis of acetylcholine, which plays a central role in the initiation and propagation of neural impulse in the CNS as well as it does in the skeletal and myocardial muscles. Pyridoxine or vitamin B6 plays a role in the synthesis of neurotransmitters such as dopamine as well as in the metabolism of tryptophan, resulting in an increase in serotonin so providing well-being and anxiety relief. Pyridoxine is essential for the proper functioning of the CNS (including at nausea and vomiting center). Cyancobalamin or Vitamin B12 plays a role in the growth and repair of nerve fibers. Importantly it also improves blood flow in the brain, with secondary vertigo improvement. The combined use of these substances provides relief of vertigo due to motion sickness. Zingiber officinale is a species of the Zingiberacaea family, widely used in traditional and herbal medicine for the treatment of various clinical conditions such as vertigo. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05221892
Study type	Interventional
Source	Fundação Educacional Serra dos Órgãos
Contact
Status	Completed
Phase	Phase 4
Start date	November 22, 2021
Completion date	March 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05649891` - Checklists Resuscitation Emergency Department	N/A
Recruiting	`NCT05533840` - Establishment and Application of a New Imaging System for Otology Based on Ultra-high Resolution CT
Completed	`NCT02533739` - Vestibular Disorder and Visuo-spatial Functions	N/A
Completed	`NCT01153789` - Study of Oculomotor Dysfunction Leading to Children Vertigo	N/A
Completed	`NCT00765635` - Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal	Phase 4
Not yet recruiting	`NCT04929444` - Training to Improve Vertigo Management in Primary Care	N/A
Completed	`NCT04458376` - Internet-based Self-help Program for Vestibular Rehabilitation in Chronic Dizziness	N/A
Not yet recruiting	`NCT04055766` - A Diagnostic Test on DeepDoc-an AI-based Decision Support System
Recruiting	`NCT06332326` - Investigation of the Efficacy of Non-Invasive Vagus Nerve Stimulation and Physiotherapy in Unilateral Vestibular Hypofunction Patients	N/A
Completed	`NCT02938221` - Telemedical Examination of a Three-Component Oculomotor Testing Battery	N/A
Active, not recruiting	`NCT02655575` - Assessment and Treatment of Patients With Long-term Dizziness in Primary Care	N/A
Completed	`NCT02457455` - Urgent Medical and Surgical Conditions During Flights	N/A
Enrolling by invitation	`NCT01426932` - The Head Impulse Test in the Screening of Vestibular Function	N/A
Completed	`NCT00000359` - Treatments for Benign Paroxysmal Positional Vertigo (BPPV)	Phase 2
Not yet recruiting	`NCT06010550` - Validating a Clinical Decision Support Tool for Stratifying Stroke Risk for Dizziness/Vertigo
Not yet recruiting	`NCT06017466` - Translation and Implementation of the Dutch VVAS Score in Clinical Practice	N/A
Completed	`NCT04598113` - Effect of Cervical Traction on Balance in Cervical Radiculopathy Patients	N/A
Completed	`NCT05157399` - Quantification of the Effect of the OtoBand on Objective Measures of Vertigo and Dizziness	N/A
Completed	`NCT05897853` - Impact of Vertigoheel® on Patients Suffering From Bilateral Vestibulopathy and Functional Dizziness
Completed	`NCT02253524` - Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine and Cyanocobalamin as Therapy for Vertigo

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms